Synthesis and biological evaluation of 2-heteroarylthioalkanoic acid analogues of clofibric acid as peroxisome proliferator-activated receptor α agonists

Journal of Medicinal Chemistry

Volumn 52, Issue 20, 2009, Pages 6224-6232

  Giampietro, Letizia ^a   Ammazzalorso, Alessandra ^a   Giancristofaro, Antonella ^a   Lannutti, Fabio ^a   Bettoni, Giancarlo ^a   De Filippis, Barbara ^a   Fantacuzzi, Marialuigia ^a   Maccallini, Cristina ^a   Petruzzelli, Michele ^b,c   Morgano, Annalisa ^a   Moschetta, Antonio ^b,c   Amoroso, Rosa ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b Dipartimento di Farmacologia Traslazionale   (Italy)

^c UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL)UREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; 2 [4 [3 [4,5 DIHYDRO 1 (4 METHYLBENZYL) 5 OXO 1H 1,2,4 TRIAZOL 3 YL]PROPYL]PHENOXY] 2 METHYLPROPIONIC ACID; 2 HETEROARYLTHIOALKANOIC ACID DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; CLOFIBRIC ACID; KCL 1998001079; NS 220; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; THIOPHENE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; GENE INDUCTION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA;

CELL LINE, TUMOR; CLOFIBRIC ACID; HUMANS; OXYGEN; PPAR ALPHA; STEREOISOMERISM; SULFUR; TRANSCRIPTIONAL ACTIVATION;

EID: 70350061743     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900878u     Document Type: Article

References (43)

1. (a) Issemann, I.; Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347, 645-650. (Pubitemid 20356241)
2. (b) Motojima, K. Peroxisome proliferator-activated receptor (PPAR): structure, mechanisms of activation and diverse functions. Cell Struct. Funct. 1993, 18, 267-277.
3. (c) Zoete, V.; Grosdidier, A.; Michielin, O. Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim. Biophys. Acta 2007, 1771, 915-925.
4. (d) Vanden Heuvel, J. P. The PPAR resource page. Biochim. Biophys. Acta 2007, 1771, 1108-1112.
5. (a) Berger, J.; Moller, D. E. The mechanisms of action of PPARs. Annu. Rev. Med. 2002, 53, 409-435.
6. (b) Kota, B. P.; Huang, T. H-W.; Roufogalis, B. D. An overview on biological mechanisms of PPARs. Pharmacol. Res. 2005, 51, 85-94.
7. (c) Feige, J. N.; Gelman, L.; Michalik, L.; Desvergne, B.; Wahli, W. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog. Lipid Res. 2006, 45, 120-159.
8. (a) Forman, B. M.; Chen, J.; Evans, R. M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 4312-4317.
9. (b) Kliewer, S. A.; Sundseth, S. S.; Jones, S. A.; Brown, P. J.; Bruce Wisely, G.; Koble, C. S.; Devchand, P.; Wahli, W.; Willson, T. M.; Lenhard, J. M.; Lehmann, J. M. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 4318-4323.
10. (c) Bishop-Bailey, D.; Wray, J. Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation. Prostaglandins Other Lipid Mediators 2003, 71, 1-22. (Pubitemid 36428519)
11. (d) Grimaldi, P. A. Peroxisome proliferator-activated receptors as sensors of fatty acids and derivatives. Cell. Mol. Life Sci. 2007, 64, 2459-2464.
12. (a) van Raalte, D. H.; Li, M.; Pritchard, P. H.; Wasan, K. M. Peroxisome proliferator-activated receptor (PPAR)-α: a pharmacological target with a promising future. Pharm. Res. 2004, 21, 1531.
13. (b) Lefebvre, P.; Chinetti, G.; Fruchart, J. C.; Bart Staels, B. Sorting out the roles of PPARα in energy metabolism and vascular homeostasis. J. Clin. Invest. 2006, 116, 571-580.
14. (a) Gouni-Berthold, I.; Krone, W. Peroxisome proliferator-activated receptorα (PPARα) and atherosclerosis. Curr. Drug Targets: Cardiovasc. Haematol. Disord. 2005, 5, 513-525.
15. (b) Israelian-Konaraki, Z.; Reaven, P. D. Peroxisome proliferator- activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications. Cardiol. Rev. 2005, 13, 240-246.
16. (c) Duval, C.; Muller, M.; Kersten, S. PPARα and dyslipidemia. Biochim. Biophys. Acta 2007, 1771, 961-971.
17. (d) Zandbergen, F.; Plutzky, J. PPARα in atherosclerosis and inflammation. Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 2007, 1771, 972-982.
18. (e) Cheng, A. Y. Y.; Leiter, L. A. PPAR-α: therapeutic role in diabetes-related cardiovascular disease. Diabetes, Obes. Metab. 2008, 9, 691-698.
19. (a) Miyachi, H. Synthetic ligands for peroxisome proliferator-activated receptor-α, review of the patent literature 2000-2003. Expert Opin. Ther. Pat. 2004, 14, 607-618.
20. (b) Balakumar, P.; Rose, M.; Singh, M. PPAR ligands: are they potential agents for cardiovascular disorders? Pharmacology 2007, 80, 1-10.
21. (c) Fruchart, J. C. Novel peroxisome proliferator activated receptor-α agonists. Am. J. Cardiol. 2007, 100, 41-46.
22. (a) Schoonjans, K.; Staels, B. M; Auwerx, J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. 1996, 37, 907-925. (Pubitemid 26182326)
23. (b) Staels, B.; Auwerx, J. Role of PPAR in the pharmacological regulation of lipoprotein metabolism by fibrates and thiazolidinediones. Curr. Pharm. Des. 1997, 3, 1-14.
24. (c) Fruchart, J. C.; Duriez, P.; Staels, B. Molecular mechanism of action of the fibrates. J. Soc. Biol. 1999, 193, 67-75.
25. (d) Chapman, M. J. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003, 171, 1-13.
26. (e) Chinetti-Gbaguidi, G.; Fruchart, J. C.; Staels, B. Pleiotropic effects of fibrates. Curr. Atheroscler. Rep. 2005, 7, 396-401.
27. (f) Barter, P. J.; Rye, K.-A. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler., Thromb., Vasc. Biol. 2008, 28, 39-46.
28. (g) Staels, B.; Maes, M.; Zambon, A. Fibrates and future PPARα agonists in the treatment of cardiovascular disease. Nat. Clin. Pract. Cardiovasc. Med. 2008, 5, 542-553.
29. Brown, P. J.; Stuart, L. W.; Hurley, K. P.; Lewis, M. C.; Winegar, D. A.; Wilson, J. G.; Wilkison, W. O.; Ittoop, O. R.; Willson, T. M. Identification of a subtype selective human PPAR agonist through parallel-array synthesis. Bioorg. Med. Chem. Lett. 2001, 11, 1225-1227.
30. (a) Nomura, M.; Tanase, T.; Ide, T.; Tsunoda, M.; Suzuki, M.; Uchiki, H.; Murakami, K.; Miyachi, H. Design, synthesis and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor α subtype-selective activators. J. Med. Chem. 2003, 46, 3581-3599.
31. (b) Miyachi, H.; Uchiki, H. Bioorg. Med. Chem. Lett. 2003, 13, 3145-3149.
32. Xu, Y.; Mayhugh, D.; Saeed, A.; Wang, X.; Thompson, R. C.; Dominianni, S. J.; Kauffman, R. F.; Singh, J.; Bean, J. S.; Bensch, W. R.; Barr, R. W.; Osborne, J.; Montrose-Rafizadeh, C.; Zink, R. W.; Yumibe, N. P.; Huang, N.; Luffer-Atlas, D.; Rungta, D.; Maise, D. E.; Mantlo, N. B. Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor α agonist. J. Med. Chem. 2003, 46, 5121-5124.
33. Shi, G. Q.; Dropinski, J. F.; Zhang, Y.; Santini, C.; Sahoo, S. P.; Berger, J. P.; MacNaul, K. L.; Zhou, G.; Agrawal, A.; Alvaro, R.; Cai, T-q.; Hernandez, M.; Wright, S. D.; Moller, D. E.; Heck, J. V.; Meinke, P. T. Novel 2,3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARα agonists with potent hypolipidemic activity. J. Med. Chem. 2005, 48, 5589-5599.
34. Matthews, J. M.; Chen, X.; Cryan, E.; Hlasta, D. J.; Rybczynski, P. J.; Strauss, K.; Tang, Y.; Xu, June, Z.; Yang, M.; Zhou, L.; Demarest, K. T. Design and synthesis of indane-ureido-thioisobutyric acids: a novel class of PPARr agonists. Bioorg. Med. Chem. Lett. 2007, 17, 6773-6778.
35. (a) Asaki, T.; Aoki, T.; Hamamoto, T.; Sugiyama, Y.; Ohmachi, S.; Kuwabara, K.; Murakami, K; Todo, M. Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor α (PPARα) agonists. Bioorg. Med. Chem. 2008, 16, 981-994. (Pubitemid 351163042)
36. (b) Aoki, T.; Asaki, T.; Hamamoto, T.; Sugiyama, Y.; Ohmachi, S.; Kuwabara, K.; Murakami, K; Todo, M. Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor α (PPARα) agonists. Bioorg. Med. Chem. Lett. 2008, 18, 2128-2132.
37. Ammazzalorso, A.;Amoroso, R.;Baraldi, M.;Bettoni, G.;Braghiroli, D.; De Filippis, B.; Giampietro, L.; Tricca, M. L.; Vezzalini, F. Synthesis and antiplatelet activity of thioaryloxyacids analogues of clofibric acid. Eur. J. Med. Chem. 2005, 40, 918-921.
38. Zhu, L.; Zhang, M.; Dai, M. A convenient synthesis of 2-mercapto and 2-chlorobenzothiazoles. J.Heterocycl.Chem. 2005, 42, 727-730.
39. Schulman, I. G.; Heyman, R. A. The flip side: identifying small molecule regulators of nuclear receptors. Chem.Biol. 2004, 11, 639-646.
40. Rangwala, S. M.; O'Brien, M. L.; Tortorella, V.; Longo, A.; Loiodice, F.; Noonan, D. J.; Feller, D. R. Stereoselective effects of chiral clofibric acid analogs on rat peroxisome proliferator-activated receptor (rPPAR) activation and peroxisomal fatty acid-oxidation. Chirality 1997, 9, 37-47.
41. Fracchiolla, G; Laghezza, A.; Piemontese, L.; Carbonara, G.; Lavecchia, A.; Tortorella, P.; Crestani, M.;Novellino, E.; Loiodice, F. Synthesis, biological evaluation, and molecular modeling investigation of chiral phenoxyacetic acid analogues with PPARα and PPARγ agonist activity. ChemMedChem 2007, 14, 641-654.
42. Miyachi, H.; Nomura, M.; Tanase, T.; Suzuki, M.; Murakami, K.; Awano, K. Enantio-dependent binding and transactivation of optically active phenylpropanoic acid derivatives at human peroxisome proliferator-activated receptor alpha. Bioorg. Med. Chem. Lett. 2002, 12, 333-335.
43. Lawrence, J. W.; Li, Y.; Chen, S.; De Luca, J. G.; Berger, J. P.; Umbenhauer, D. R.; Moller, D. E.; Zhou, G. Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha. PPAR alpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expression. J. Biol. Chem. 2001, 276, 31521-31527.